

Anti-PD-L1 (Atezolizumab), humanized Antibody

Human Monoclonal Antibody

Catalog # ABV12036

Product Information

Application	E
Primary Accession	Q9NZQ7
Reactivity	Human
Host	Human
Clonality	Monoclonal
Isotype	Human IgG1
Clone Names	N/A
Calculated MW	33275

Additional Information

Gene ID	29126
Other Names	Tecentriq, PD-L1
Target/Specificity	PD-L1
Antibody Form	Liquid
Appearance	Colorless liquid
Formulation	In phosphate buffered saline, pH 7.4
Handling	The antibody solution should be gently mixed before use.
Reconstitution & Storage	-20 °C
Background Descriptions	
Precautions	Anti-PD-L1 (Atezolizumab), humanized Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	CD274 (HGNC:17635)
Function	Plays a critical role in induction and maintenance of immune tolerance to self (PubMed: 11015443 , PubMed: 28813410 , PubMed: 28813417 , PubMed: 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed: 11015443 , PubMed: 28813410 , PubMed: 28813417 , PubMed: 36727298). Through a yet unknown activating receptor, may

costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:[10581077](#)). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:[32929201](#)).

Cellular Location

Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein. Nucleus. Note=Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation (PubMed:28813417). Translocates to the nucleus in response to hypoxia via its interaction with phosphorylated STAT3 (PubMed:32929201). [Isoform 2]: Endomembrane system; Single-pass type I membrane protein

Tissue Location

Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.

Background

Atezolizumab (Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with PD-1 and induces anti-tumor immune reactivation.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.